Hyphens Pharma's Q3 Net Profit Falls to $2m
Hyphens Pharma's Q3 Net Profit Falls to $2m
Revenue rose 2.5% year-on-year from $42.8m to $43.9m, driven by stronger sales in Singapore and Malaysia. Meanwhile, revenue rose thanks to stronger sales in Singapore and Malaysia.
與此同時，由於新加坡和馬來西亞銷售增長，營業收入也同比上漲。
Hyphens Pharma International Limited's net profit for the third quarter fell by 5.6% to $2m, down from $2.1m in the same period last year, its bourse filing showed.
凱帆藥劑國際有限公司第三季度淨利潤下降了5.6%，至200萬美元，低於去年同期的210萬美元，根據其交易所文件顯示。
The group attributed the decline to higher distribution and manpower costs and increased administrative expenses. This was partially offset by a higher gross profit and exchange gains from favourable currency movements against the US dollar and euro.
該集團歸因於較高的銷售和人力成本以及增加的行政費用導致淨利潤下降。這在一定程度上被較高的毛利潤和有利匯率波動使美元和歐元貶值所抵消。
Revenue rose 2.5% year-on-year from $42.8m to $43.9m, driven by stronger sales in Singapore and Malaysia.
營業收入同比增長2.5%，從4280萬美元增至4390萬美元，得益於新加坡和馬來西亞銷售增長。
September revenue increased by 22.1% to $143.5m, mainly due to growth in the specialty pharma principals segment, including new sales from distributorships with Laboratoires Gilbert S.A.S and higher demand for its medical aesthetics range.
9月份營收增長了22.1%，達到14350萬元，主要是由於特殊藥劑貿易代理商細分市場的增長，包括與Laboratoires Gilbert S.A.S的經銷合作新銷售以及其醫療美容區間需求的增加。
Revenue from the proprietary brands segment grew by 16.9%, whilst the medical hypermart and digital segments posted a 3% increase.
專有品牌部門的營收增長了16.9%，而醫療超市和數字部門實現了3%的增長。
